BusinessBelgium

ThromboGenics in eye drug deal with Novartis unit Alcon

19.03.2012 - Biopharmaceutical company ThromboGenics has entered into an agreement with Alcon Inc., a division of Novartis for the commercialisation of its product ocriplasmin in all markets outside the U.S.

ThromboGenics said it will concentrate on commercialising ocriplasmin in the U.S., where it plans to build its commercial and medical organisation to support the anticipated launch of the eye drug within the next 12 months. The truncated form of the human serine protease plasmin is under review in Europe for the indication symptomatic vitreomacular adhesion. ThromboGenics will receive an up-front payment of €75m and is eligible for a further €90m in potential near-term milestone payments. Additional milestones would bring the potential total of up-fronts and milestones to €375m according to ThromboGenics. The Belgian company will have a "strategic and focused operational role" in the commercialisation of the product in the five largest European markets. The partners will also co-develop ocriplasmin in additional indications, with both companies responsible for development costs. Details were not disclosed. Ocriplasmin is Thrombogenics' lead product. It represents an injectable recombinant microplasmin, a truncated form of the natural human protein plasmin. The drug has successfully completed two Phase III clinical trials for the pharmacological treatment of the eye disease symptomatic vitreomacular adhesion.

http://www.european-biotechnology-news.com/news/news/2012-01/thrombogenics-in-eye-drug-deal-with-novartis-unit-alcon.html

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)1.75 EUR16.67%
  • SWEDISH ORPHAN BIOVITRUM (S)13.11 USD6.59%
  • RENEURON (UK)3.15 GBP5.00%

FLOP

  • VECTURA (UK)148.80 GBP-4.25%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%
  • BONE THERAPEUTICS SA (B)16.05 EUR-3.31%

TOP

  • PROTHENA PLC (IE)52.22 USD47.2%
  • FLAMEL TECHNOLOGIES (F)12.58 USD33.1%
  • DBV TECHNOLOGIES (F)64.40 EUR26.3%

FLOP

  • MOLOGEN (D)1.75 EUR-30.0%
  • EVOCUTIS (UK)0.04 GBP-20.0%
  • SAREUM HOLDINGS (UK)0.62 GBP-19.5%

TOP

  • KARO BIO (S)29.80 SEK1774.2%
  • NICOX (F)11.20 EUR474.4%
  • SAREUM HOLDINGS (UK)0.62 GBP158.3%

FLOP

  • BB BIOTECH (D)45.00 EUR-84.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.72 SEK-78.9%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 25.07.2016